BCIQ Profiles

Company Profile ReportTarget Profile Report

Sobi buying Novimmune assets as it refocuses R&D

Less than a year after gaining an exclusive worldwide license for Gamifant emapalumab from Novimmune, Sobi is acquiring a newco formed around the hematology therapy for CHF515 million ($519.2 million) and

Read the full 312 word article

How to gain access

Continue reading with a
two-week free trial.